Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the sale, the director now owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Simulations Plus Stock Performance
NASDAQ SLP opened at $31.33 on Wednesday. The company has a market cap of $628.79 million, a P/E ratio of 63.94 and a beta of 0.76. The business's 50 day moving average price is $30.83 and its 200-day moving average price is $37.30. Simulations Plus, Inc. has a fifty-two week low of $27.07 and a fifty-two week high of $51.22.
Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 earnings per share. The business's revenue for the quarter was up 19.9% on a year-over-year basis. As a group, equities analysts predict that Simulations Plus, Inc. will post 1.12 EPS for the current year.
Analyst Upgrades and Downgrades
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research | Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.
Several brokerages have recently issued reports on SLP. Stephens initiated coverage on Simulations Plus in a report on Friday, November 15th. They issued an "overweight" rating and a $39.00 target price on the stock. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, November 6th. StockNews.com downgraded Simulations Plus from a "hold" rating to a "sell" rating in a research report on Monday, November 4th. Finally, BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Simulations Plus currently has an average rating of "Moderate Buy" and an average target price of $51.40.
Check Out Our Latest Analysis on SLP
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of SLP. Public Employees Retirement System of Ohio purchased a new position in Simulations Plus during the 1st quarter valued at $1,082,000. Deerfield Management Company L.P. Series C bought a new stake in shares of Simulations Plus during the second quarter worth $811,000. US Bancorp DE grew its holdings in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock worth $159,000 after purchasing an additional 1,343 shares during the last quarter. Royce & Associates LP increased its stake in Simulations Plus by 28.8% in the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company's stock worth $7,602,000 after buying an additional 53,092 shares during the period. Finally, Tributary Capital Management LLC lifted its holdings in Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company's stock valued at $10,425,000 after buying an additional 115,122 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company's stock.
About Simulations Plus
(
Get Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
